Meiji Yasuda Asset Management CO Ltd. Neurocrine Biosciences Inc Transaction History

Meiji Yasuda Asset Management CO Ltd.

$2.32 Billion
Q1 2024

A detailed history of Meiji Yasuda Asset Management CO Ltd. transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Meiji Yasuda Asset Management CO Ltd. holds 6,308 shares of NBIX stock, worth $897,249. This represents 0.04% of its overall portfolio holdings.

Number of Shares

6,308

Previous 9,040 30.22%

Holding current value

$897,249

Previous $1.19 Million 27.04%

% of portfolio

0.04%

Previous 0.05%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$130.4 - $143.74 $356,252 - $392,697	-2,732 Reduced 30.22%	6,308 $869,000
Q4 2023 Feb 14, 2024	BUY	$106.07 - $132.76 $118,798 - $148,691	1,120 Added 14.14%	9,040 $1.19 Million
Q3 2023 Nov 13, 2023	BUY	$94.02 - $117.1 $468,219 - $583,158	4,980 Added 169.39%	7,920 $891,000
Q2 2023 Aug 14, 2023	BUY	$89.53 - $104.87 $51,927 - $60,824	580 Added 24.58%	2,940 $277,000
Q1 2023 May 09, 2023	SELL	$94.11 - $123.02 $369,852 - $483,468	-3,930 Reduced 62.48%	2,360 $239,000

Q3 2022 Nov 14, 2022	SELL	$92.03 - $107.81 $12,884 - $15,093	-140 Reduced 2.18%	6,290 $668,000
Q2 2022 Aug 16, 2022	BUY	$75.79 - $100.07 $9,094 - $12,008	120 Added 1.9%	6,430 $627,000
Q1 2022 May 17, 2022	SELL	$72.45 - $94.81 $8,694 - $11,377	-120 Reduced 1.87%	6,310 $592,000
Q4 2021 Feb 14, 2022	BUY	$79.65 - $106.22 $512,149 - $682,994	6,430 New	6,430 $548,000
Q2 2021 Aug 13, 2021	SELL	$89.43 - $102.27 $438,207 - $501,123	-4,900 Closed	0 $0
Q1 2021 May 14, 2021	BUY	$87.57 - $119.4 $35,903 - $48,954	410 Added 9.13%	4,900 $477,000
Q4 2020 Feb 12, 2021	BUY	$86.91 - $108.33 $390,225 - $486,401	4,490 New	4,490 $430,000

Others Institutions Holding NBIX

# of Institutions

628

Shares Held

94.4M

Call Options Held

505K

Put Options Held

343K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $13.6B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Meiji Yasuda Asset Management CO Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Meiji Yasuda Asset Management CO Ltd. with notifications on news.

Account

Meiji Yasuda Asset Management CO Ltd. Neurocrine Biosciences Inc Transaction History